phenyl acetate has been researched along with Atherosclerotic Parkinsonism in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ajayi, AM; Alabi, AO; Bakre, AG; Ben-Azu, B; Umukoro, S | 1 |
Bagga, P; Chugani, AN; Patel, AB; Varadarajan, KS | 1 |
Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL | 1 |
1 trial(s) available for phenyl acetate and Atherosclerotic Parkinsonism
Article | Year |
---|---|
Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial.
Topics: Acetates; Adult; Aged; Amines; Antiparkinson Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Method; Electromyography; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Tremor | 1997 |
2 other study(ies) available for phenyl acetate and Atherosclerotic Parkinsonism
Article | Year |
---|---|
Methyl jasmonate abrogates rotenone-induced parkinsonian-like symptoms through inhibition of oxidative stress, release of pro-inflammatory cytokines, and down-regulation of immnopositive cells of NF-κB and α-synuclein expressions in mice.
Topics: Acetates; alpha-Synuclein; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Behavior, Animal; Brain Chemistry; Cyclopentanes; Cytokines; Male; Mice; NF-kappa B; Oxidative Stress; Oxylipins; Parkinson Disease, Secondary; Psychomotor Performance; Rotenone; Uncoupling Agents | 2019 |
In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment.
Topics: Acetates; Algorithms; Animals; Antiparkinson Agents; Blood Glucose; Brain Chemistry; Energy Metabolism; Glutamates; Hand Strength; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neostriatum; Oxidation-Reduction; Parkinson Disease, Secondary; Psychomotor Performance; Radiopharmaceuticals | 2013 |